Intellia Therapeutics, Inc.
NASDAQ:NTLA
9.14 (USD) • At close March 14, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 57.877 | 36.275 | 52.121 | 33.053 | 57.994 | 43.103 | 30.434 | 26.117 | 16.479 | 6.044 | 0 |
| Kosten van de omzet
| 0 | 8.976 | 7.572 | 6.891 | 150.408 | 108.413 | 89.115 | 67.647 | 31.84 | 11.17 | 1.658 |
| Brutowinst
| 57.877 | 27.299 | 44.549 | 26.162 | -92.414 | -65.31 | -58.681 | -41.53 | -15.361 | -5.126 | -1.658 |
| Brutowinstmarge
| 1 | 0.753 | 0.855 | 0.792 | -1.594 | -1.515 | -1.928 | -1.59 | -0.932 | -0.848 | 0 |
| Onderzoek- en ontwikkelingskosten
| 466.311 | 435.069 | 419.979 | 229.807 | 150.408 | 108.413 | 89.115 | 67.647 | 31.84 | 11.17 | 10.74 |
| Algemene en administratieve kosten
| 125.829 | 116.497 | 90.306 | 71.096 | 44.169 | 41.058 | 32.189 | 28.025 | 16.798 | 8.283 | 3.569 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 125.829 | 116.497 | 90.306 | 71.096 | 44.169 | 41.058 | 32.189 | 28.025 | 16.798 | 8.283 | 3.569 |
| Overige kosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 592.14 | 551.566 | 510.285 | 300.903 | 194.577 | 149.471 | 121.304 | 95.672 | 48.638 | 19.453 | 12.651 |
| Bedrijfsresultaat
| -534.263 | -515.291 | -458.164 | -267.85 | -136.583 | -106.368 | -90.87 | -69.555 | -32.159 | -13.409 | -5.226 |
| Bedrijfsresultaat ratio
| -9.231 | -14.205 | -8.79 | -8.104 | -2.355 | -2.468 | -2.986 | -2.663 | -1.952 | -2.219 | 0 |
| Totaal overige inkomsten en kosten netto
| 15.242 | 34.099 | -16.022 | -0.042 | 2.352 | 6.835 | 5.527 | 2.012 | 0.525 | 0 | -9.083 |
| Inkomen voor belasting
| -519.021 | -481.192 | -474.186 | -267.892 | -134.231 | -99.533 | -85.343 | -67.543 | -31.634 | -13.409 | -14.309 |
| Inkomen voor belasting ratio
| -8.968 | -13.265 | -9.098 | -8.105 | -2.315 | -2.309 | -2.804 | -2.586 | -1.92 | -2.219 | 0 |
| Belastingkosten
| 0 | 0 | 16.022 | -8.174 | -8.663 | -6.835 | 5.527 | -2.994 | -1.104 | -1.012 | 0 |
| Nettowinst
| -519.021 | -481.192 | -490.208 | -259.718 | -125.568 | -92.698 | -85.343 | -67.543 | -31.634 | -12.397 | -14.309 |
| Nettowinstmarge
| -8.968 | -13.265 | -9.405 | -7.858 | -2.165 | -2.151 | -2.804 | -2.586 | -1.92 | -2.051 | 0 |
| WPA (Winst Per Aandeel)
| -5.25 | -5.42 | -6.37 | -3.66 | -2.24 | -1.96 | -1.98 | -1.88 | -1.42 | -0.7 | -29.45 |
| Verwaterde WPA
| -5.25 | -5.42 | -6.37 | -3.66 | -2.24 | -1.96 | -1.98 | -1.88 | -1.42 | -0.7 | -29.45 |
| EBITDA
| -523.978 | -506.315 | -450.592 | -260.959 | -130.272 | -100.781 | -86.406 | -66.561 | -31.055 | -13.081 | -9.536 |
| EBITDA ratio
| -9.053 | -13.958 | -8.532 | -8.104 | -2.355 | -2.338 | -2.986 | -2.663 | -1.952 | -2.164 | 0 |